EndoPredict Publications

2019
Dec 2019

Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results.

Noske A, Anders SI, Ettl J, Hapfelmeier A, Steiger K, Specht K, Weichert W, Kiechle M, Klein E.

Breast. 2020; 49:101-7. [In Progress]

Dec 2019

Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EPclin) use (UCBG 2-14).

Penault-Llorca F, Kwiatkowski F, Arnaud A, Levy C, Leheurteur M, Uwer L, Derbel O, Le Rol A, Jacquin JP, Jouannaud C, Quenel-Tueux N, Girre V, Foa C, Guardiola E, Lortholary A, Catala S, Guiu S, Valent A, Boinon D, Lemonnier J, Delaloge S.

Breast. 2020; 49:132-40. [In Progress]

Aug 2019

Predicting Expected Absolute Chemotherapy Treatment Benefit in Women With Early-Stage Breast Cancer Using EndoPredict, an Integrated 12-Gene Clinicomolecular Assay.

Soliman H, Flake II DD, Magliocco A, Robson M, Schwartzberg L, Sharma P, Brown K, Wehnelt S, Kronenwett R, Gutin A, Lancaster J, Cuzick J, Gradishar W.

JCO Precis Oncol 2019 [Epub ahead of print]

May 2019

Cost-effectiveness analysis of multigene expression profiling assays to guide adjuvant therapy decisions in women with invasive early-stage breast cancer.

Hannouf MB, Zaric GS, Blanchette P, Brezden-Masley C, Paulden M, McCabe C, Raphael J, Brackstone M.

Pharmacogenomics J. 2019 [Epub ahead of print]

May 2019

Prediction of Distant Recurrence using EndoPredict among Women with ER+, HER2- Node- Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only.

Filipits M, Dubsky P, Rudas M, Greil R, Balic M, Bago-Horvath Z, Singer C, Hlauschek D, Brown K, Bernhisel R, Kronenwett R, Lancaster J, Fitzal F, Gnant M.

Clin Cancer Res. 2019;25:3865-72.

May 2019

Prognostic value of EndoPredict for invasive lobular carcinomas in the combined ABCSG-6/8 and TransATAC trials.

Sestak I, Filipits M, Buus R, Kronenwett R, Knauer M, Cuzick J, Dowsett M, Dubsky P.

Abstract: Ann Oncol. 30;2019 (suppl 3; abstr iii20).

Apr 2019

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone.

Sestak I, Martin M, Dubsky P, Kronenwett R, Rojo F, Cuzick J, Filipits M, Ruiz A, Gradishar W, Soliman H, Schwartzberg L, Buus R, Hlauschek D, Rodriguez A, Gnant M.

Breast Cancer Res Treat. 2019; 176:377-86.

Feb 2019

The impact of EndoPredict® on decision making with increasing oncological work experience: can overtreatment be avoided?

Thangarajah F, Eichler C, Fromme J, Malter W, Radosa JC, Ludwig S, Puppe J, Paepke S, Warm M.

Arch Gynecol Obstet. 2019;299:1437–42.

2018
Dec 2018

First prospective outcome data for the clinico-molecular test EndoPredict® in hormone receptor positive, HER2-negative early breast cancer in clinical routine.

Ettl J, Anders KS, Hapfelmeier A, Paepke S, Noske A, Weichert W, Klein E, Kiechle M.

Poster: SABCS 2018; P4-08-11.

Dec 2018

EndoPredict prognostic signature in pN1mi, estrogen receptor-positive breast cancer: analysis of the French national registry for molecular signatures.

Lacroix-Triki M, Arnould L, MacGrogan G, Penault-Llorca F, Haudebourg J, Tas P, Garnier A, Vincent-Salomon A, Miquel C, Lehmann-Che J, Callens C, Quillien V, Cayre A, Lamy PJ, Rouleau E, de Cremoux P.

Poster: SABCS 2018; P4-08-23.

Dec 2018

Change in therapeutic management after EndoPredict assay in a prospective decision impact study of Mexican premenopausal breast cancer patients.

Villarreal-Garza C, Deneken-Hernandez Z, Maffuz-Aziz A, Lopez-Martinez EA, Muñoz-Lozano JF, Barragan-Carrillo R, Peña-Curiel O, Moreno-Jaime B, Ramos-Elias P, Diaz H, Bautista-Piña V, Garcia-Garcia M, Mesa-Chavez F.

Poster: SABCS 2018; P2-08-54.

Dec 2018

RESCUE: REACHING FOR EVIDENCE-BASED CHEMOTHERAPY USE IN ENDOCRINE SENSITIVE BREAST CANCER, A prospective health care study on risk assessment by the clinicomolecular test EndoPredict® and long-term patient outcome in early luminal breast cancer.

Ettl J, Blohmer J-U, Denkert C, Keller M, Klein E, Kronenwett R, Neuser P, Paepke S, Schade-Brittinger C, Schnuppe K, Untch M, Wittenberg M, Kiechle M.

Poster: SABCS 2018; OT1-12-03.

Aug 2018

The impact of EndoPredict clinical score on chemotherapy recommendations in women with invasive ER+/HER2- breast cancer stratified as having moderate or poor prognosis by Nottingham Prognostic Index.

Mokbel K, Wazir U, Wazir A, Kasem A, Mokbel K.

Anticancer Res. 2018;38:4747-52.

Jul 2018

Risk assessment after neoadjuvant chemotherapy in luminal breast cancer using a clinicomolecular predictor.

Loibl S, Weber K, Huober J, Krappmann K, Marmé F, Schem C, Engels K, Pfitzner BM, Kümmel S, Furlanetto J, Hartmann A, Darb-Esfahani S, Müller V, Staebler A, von Minckwitz G, Kronenwett R, Denkert C.

Clin Cancer Res. 2018;24:3358-65.

Jun 2018

In silico evaluation of the 12-gene molecular score (EndoPredict) and the recurrence score (Oncotype DX) as predictors of response to neoadjuvant chemotherapy in estrogen receptor positive, HER2 negative breast cancer.

Soliman H, Robson M, Wagner S, Flake II DD, Schwartzberg L, Sharma P, Magliocco A, Kronenwett R, Lancaster J, Lanchbury JS, Gutin A, Gradishar W.

Abstract: J Clin Oncol 36, 2018 (suppl; abstr 539).

Jun 2018

Predicting expected absolute chemotherapy treatment benefit in women with early-stage breast cancer using a 12-gene expression assay.

Gradishar W, Robson M, Flake II DD, Schwartzberg L, Sharma P, Soliman H, Magliocco A, Brown K, Wehnelt S, Gutin A, Kronenwett R, Lancaster J.

Abstract: J Clin Oncol 36, 2018 (suppl; abstr 525).

May 2018

First French pilot quality assessment of the EndoPredict test for early luminal breast carcinoma.

Lehmann-Che J, Miquel C, Wong J, Callens C, Rouleau E, Quillien V, Lozano N, Cayre A, Lacroix L, Bieche I, Bertheau P, Teixeira L, Llorca FP, Lamy PJ, DE Cremoux P; GFCO GROUP.

Anticancer Res. 2018;38:2909-14.

Apr 2018

Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial.

Sestak I, Buus R, Cuzick J, Dubsky P, Kronenwett R, Denkert C, Ferree S, Sgroi D, Schnabel C, Baehner FL, Mallon E, Dowsett M.

JAMA Oncol. 2018;4:545-53.

Apr 2018

Enhancing decision-making about adjuvant chemotherapy in early breast cancer following EndoPredict testing.

Fallowfield L, Matthews L, May S, Jenkins V, Bloomfield D.

Psychooncology. 2018;27:1264-69.

Feb 2018

Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict’s value.

Chow LWC, Morita S, Chow CYC, Ng WK, Toi M.

Endocr Relat Cancer. 2018;25:123-30.

2017
Dec 2017

A comparison of the performance of EndoPredict clinical and NHS PREDICT in 120 patients treated for ER-positive breast cancer.

Mokbel K, Wazir U, El Hage Chehade H, Manson A, Choy C, Moye V, Mokbel K.

Anticancer Res. 2017;37:6863-69.

Sep 2017

Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1.

Ettl J, Klein E, Hapfelmeier A, Grosse Lackmann K, Paepke S, Petry C, Specht K, Wolff L, Höfler H, Kiechle M.

PLoS One. 2017;12:e0183917.

Sep 2017

Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer.

Peláez-García A, Yébenes L, Berjón A, Angulo A, Zamora P, Sánchez-Méndez JI, Espinosa E, Redondo A, Heredia-Soto V, Mendiola M, Feliú J, Hardisson D.

PLoS One. 2017;12:e0183452.

Aug 2017

MammaPrint versus EndoPredict: Poor correlation in disease recurrence risk classification of hormone receptor positive breast cancer.

Bösl A, Spitzmüller A, Jasarevic Z, Rauch S, Jäger S, Offner F.

PLoS One. 2017;12:e0183458.

Jun 2017

Analytical validation of a 12-gene molecular test for the prediction of distant recurrence in breast cancer.

Warf MB, Rajamani S, Krappmann K, Doedt J, Cassiano J, Brown K, Reid JE, Kronenwett R, Roa BB.

Future Sci OA. 2017; 3: FSO221.